eRNAs detected in patient-derived transcriptomic data can delineate potential active enhancer regions in oesophageal adenocarcinoma and uncover genes associated with the cancer phenotype.

Bazedoxifene's SERD activities enable it to resist the impact of activating ESR1 mutations in breast cancer.

Akt activation is required for neural crest differentiation through regulation of Sox10 activity.

Formation of a giant unilocular vacuole through a macropinocytosis-like process in cells with disrupted actin cytoskeleton promotes resistance to anoikis.

Effective antiestrogens engage a new structural interaction to improve therapeutic antagonism in hormone-resistant breast cancer cells expressing Y537S estrogen receptor alpha.

Human genomic DNA contains uracil in the late replicating, constitutive heterochromatic regions, while treatment with drugs perturbing thymidylate biosynthesis shifts the uracil distribution pattern towards the euchromatin in UNG-inhibited cells.

The first-in-class kinase inhibitor, Ibrutinib, destabilizes its autoinhibited Bruton’s tyrosine kinase (BTK) target, and a remote resistance mutation causes global structural changes that activate BTK catalytic activity.

A novel first-in-class small molecule (ERX-11) that interacts with and disrupts the interactome of the estrogen receptor (ER), blocks the growth of ER-positive breast cancers, including those that are resistant to currently approved hormonal agents.

Single-molecule tracking at scale, analyzing millions of cells and thousands of compounds per day, demonstrates that measuring protein motion provides mechanistic insights relevant to drug discovery.